Stephen Fodor, Jami Nachtsheim
Affymetrix Founder and Chairman Stephen Fodor is retiring from the company's board, effective Jan. 30. Jami Nachtsheim will succeed Fodor as Chairwoman.
Fodor founded Affy in 1992 and initially was the company's scientific director. In 1993, he was named the firm's president and served as its CEO from 1997 to 2008. He has been on the board since Affy's founding and became its chairman in 1999.
Nachtsheim has been an Affy director since 2010. Three years later, she became its lead independent director.
Roger Moody, Ann Wallin, Sheli Rosenberg
Nanosphere announced that CFO Roger Moody notified the firm this week that he will step down from his position with the firm on Feb. 11. Nanosphere has appointed Ann Wallin, currently VP of finance and accounting, to serve as interim CFO and chief accounting officer after Moody leaves the firm. In addition, Sheli Rosenberg has resigned as chair of Nanosphere's board of directors. The company said that it will conduct search for a successor chair.
Frances Heller
Frances Heller has joined Diagnostics For All's board, effective immediately. She currently is a trustee of the Dana-Farber Cancer Institute and a board member at Zafgen and Affinivax. Heller most recently was senior vice president of business development at Bristol-Myers Squibb and was a trustee of the Bristol-Myers Squibb Foundation. Before joining Bristol-Myers Squibb, she was executive vice president of business development at Exelixis Pharmaceuticals.
Norma Nowak
Norma Nowak has been named the executive director of the University at Buffalo’s Center of Excellence in Bioinformatics and Life Sciences. In addition to her role at the center, Nowak is a professor of biochemistry at UB, as well as the founder and CSO of Empire Genomics , a molecular diagnostics company focused on personalized medicine. In the past, she served as director of the Genomics Shared Resource, a collaborative research lab shared by the UB School of Medicine and Biomedical Sciences and Roswell Park Cancer Institute.
Thierry Bernard
Qiagen said this week that Thierry Bernard will join the company in February as senior vice president of the molecular diagnostics business area. Thierry has been with BioMérieux in various roles of increasing responsbility, most recently as corporate vice president, global commercial operations, investor relations, and the greater China region. He is a member of the board of directors of AdvanDx and Daktari Diagnostics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.